| Business Summary | | Maxygen,
Inc.
is
focused
on
using
its
integrated
technologies
to
create
novel
therapeutic
and
industrial
products
for
the
field
of
directed
molecular
evolution,
the
process
by
which
genes
are
modified
for
specific
commercial
uses.
The
Company's
technologies
bring
together
advances
in
molecular
biology
and
protein
modification
to
create
biotechnology
products.
At
December
31,
2000,
the
Company
was
working
on
over
40
different
potential
products,
including
eight
potential
products
that
are
in
the
development
stage.
Maxygen's
products
will
be
developed
and
marketed
either
through
corporate
collaborations
or
independently
by
the
Company.
The
Company's
target
markets
include
protein
pharmaceuticals,
preventative
and
therapeutic
vaccines,
chemicals
and
agriculture. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Maxygen,
Inc.
in
engaged
in
the
field
of
directed
molecular
evolution,
utilizing
the
Company's
proprietary
technologies
to
mimic
the
natural
process
of
evolution
and
bring
together
advances
in
molecular
biology
and
classical
breeding.
For
the
six
months
ended
6/30/01,
revenues
rose
26%
to
$14.6
million.
Net
loss
totaled
$22.6
million,
up
from
$10
million.
Results
reflect
increased
amounts
earned
under
collaborative
R&D
agreements,
offset
by
increased
R&D
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| Isaac Stein, 53 Chairman | -- | -- | Russell Howard, Ph.D., 49 CEO,
Director | $226K | $33.8K | Simba Gill, Ph.D., 35 Pres | 195K | 1.6K | Lawrence Briscoe CFO,
Sr. VP | -- | -- | John Curd, M.D. Sr.
VP, Clinical Devel. | -- | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|